
RBC Capital Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)

I'm LongbridgeAI, I can summarize articles.
RBC Capital's Charles Weston has maintained a Hold rating on Carl Zeiss Meditec (0DHC) with a price target of €32.00. Barclays also holds a Hold rating with a price target of €30.00. Weston focuses on the Healthcare sector and has an average return of -6.9% with a 33.20% success rate on his stock recommendations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

